Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
Investigating the mechanism(s) associated with impaired tumor immunogenicity in a mouse model of breast cancer
FY 2022-23
Summary
Breast cancer is the primary cause of cancer death in women worldwide, accounting for 25% of the total cancer cases and 15% of cancer-related mortality in women. Additionally, the incidence of breast cancer in North America is on the rise. Cancer metastasis refers to the spread of tumor cells from the primary tumor to distant organs. There is currently a lack of knowledge of immunological factors that enhance breast cancer progression and metastasis. Furthermore, patients with triple-negative breast cancer (TNBC), an aggressive type of breast cancer, do not benefit from current treatment methods for metastatic cancer. Therefore, there is tremendous interest in understanding the mechanism of TNBC and distant metastasis.
CD71+ erythroid cells (CECs) are red blood cell precursors that have attracted significant attention in the cancer field due to their immunosuppressive properties. Furthermore, studies have revealed a high expression of artemin (ARTN), a neurotrophic factor, by CECs. Therefore, it is hypothesized that CECs promote tumor progression and metastasis in a mouse model of TNBC by secretion of ARTN which interacts with tumor cells. This study proposes the use of an anti-CD71 antibody to deplete CECs in mice before tumor development. Tumor size and metastasis are expected to decline upon CEC depletion. Moreover, tumor-bearing mice will be treated with an anti-ARTN antibody to block the effects of ARTN. It is expected that anti-ARTN-treated mice exhibit a smaller tumor size and significantly less tumor progression and metastasis. This study will provide a deeper understanding of factors in the breast tumor microenvironment that are associated with breast cancer progression and metastasis to tackle this major global health concern.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486132
Name
Rahmati Amirhossein
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the mechanism(s) associated with impaired tumor immunogenicity in a mouse model of breast cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Cd71+ Erythroid Precursors; Immune Suppression; Immune System; Immunology; Metastasis; Red Blood Cell Precursors; T Cells; Tumor Microenvironment; Tumor Progression
Abstract
Breast cancer is the primary cause of cancer death in women worldwide, accounting for 25% of the total cancer cases and 15% of cancer-related mortality in women. Additionally, the incidence of breast cancer in North America is on the rise. Cancer metastasis refers to the spread of tumor cells from the primary tumor to distant organs. There is currently a lack of knowledge of immunological factors that enhance breast cancer progression and metastasis. Furthermore, patients with triple-negative breast cancer (TNBC), an aggressive type of breast cancer, do not benefit from current treatment methods for metastatic cancer. Therefore, there is tremendous interest in understanding the mechanism of TNBC and distant metastasis.
CD71+ erythroid cells (CECs) are red blood cell precursors that have attracted significant attention in the cancer field due to their immunosuppressive properties. Furthermore, studies have revealed a high expression of artemin (ARTN), a neurotrophic factor, by CECs. Therefore, it is hypothesized that CECs promote tumor progression and metastasis in a mouse model of TNBC by secretion of ARTN which interacts with tumor cells. This study proposes the use of an anti-CD71 antibody to deplete CECs in mice before tumor development. Tumor size and metastasis are expected to decline upon CEC depletion. Moreover, tumor-bearing mice will be treated with an anti-ARTN antibody to block the effects of ARTN. It is expected that anti-ARTN-treated mice exhibit a smaller tumor size and significantly less tumor progression and metastasis. This study will provide a deeper understanding of factors in the breast tumor microenvironment that are associated with breast cancer progression and metastasis to tackle this major global health concern.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rahmati, Amirhossein
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~